Abbvie Inc

Amgen Inc

Regeneron Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Gilead Sciences Inc

Alnylam Pharmaceuticals Inc

argenx SE

Biogen Inc

Moderna Inc

Horizon Therapeutics PLC

Beigene Ltd

Summit Therapeutics Inc

Genmab A/S

Natera Inc

United Therapeutics Corp

Vaxcyte Inc

Biomarin Pharmaceutical Inc

Exact Sciences Corp

Karuna Therapeutics Inc

Incyte Corp

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. The company is headquartered in Waltham, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2016-04-07. The firm is engaged in creating inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4B7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, and SPY230. The company has nominated development candidates for SPY001 and SPY002. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4B7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a discovery-stage program focused on designing antibodies to bind to Interleukin 23 (IL-23).

Spyre Therapeutics Inc

Aeglea BioTherapeutics, Inc.

Spyre Средний темп роста (2 года)

Что такое Средний темп роста (2 года) ?

Какой показатель «Средний темп роста (2 года)» у Spyre ?